Sort
82,697 grants matching “vaccine development”
Plasma Cells in Health and Disease
$2,691,282Ignacio E. Sanz · Emory University · P01 · FY2023 · AI
Rapid Acting Vaccine for Pandemic Influenza
$2,691,277Corixa Corporation · UC1 · FY2005 · AI
Spore in Head and Neck Cancer
$2,691,110David Sidransky · Johns Hopkins University · P50 · FY2010 · DE
Centralized HIV-1 Genes as Vaccines
$2,690,988Barton F Haynes · Duke University · P01 · FY2009 · AI
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM
$2,689,144Fred Hutchinson Cancer Research Center · P50 · FY2003 · CA
Development of rationally designed HIV vaccines
$2,689,105Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Structure based design of antibodies and vaccines
$2,688,754James E Crowe · Vanderbilt University Medical Center · U19 · FY2019 · AI
Centers for AIDS Research (CFAR)
$2,688,655Georgia D Tomaras · Duke University · P30 · FY2022 · AI
Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases
$2,688,099Clifford Lane · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Tuberculosis Imaging Program
$2,687,710Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIC · FY2021 · AI
Plasma Cells in Health and Disease
$2,686,806Ignacio E. Sanz · Emory University · P01 · FY2024 · AI
"MALARIA VACCINE DEVELOPMENT - RAPID T CELL ANTIGEN DISCOVERY USING HUMAN T CELL SCREENS OF A P.FALCIPARUM PROTEOMIC LIBRAY"
$2,685,993Genocea Biosciences, Inc. · · FY2009 · Department of Defense
Plasma Cells in Health and Disease
$2,684,918Ignacio E. Sanz · Emory University · P01 · FY2025 · AI
Immune Modulation After Allogeneic HCT
$2,684,637Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2023 · CA
Immune Modulation After Allogeneic HCT
$2,684,637Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2022 · CA
Advanced Development of Vaccines for Infectious Diseases
$2,684,251Neal Van Hoeven · Access To Advanced Health Institute · N01 · FY2021 · AI
Preventive Vaccines for HIV
$2,684,061Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
$2,683,830Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2023 · AI
Bone Marrow Grafting for Leukemia and Lymphoma
$2,683,519Stanford University · P01 · FY2003 · CA
Membrane Remodeling in Viral Infection and Assembly and Parasite Replication
$2,682,755Joshua Zimmerberg · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2020 · HD
Systems Genetics of Tuberculosis
$2,682,482Christopher M Sassetti · Univ Of Massachusetts Med Sch Worcester · P01 · FY2025 · AI
Comprehensively Defining the Novel Alphaviral Capsid Protein / IRAK1 Interaction
$2,681,840Kevin Joseph Sokoloski · University Of Louisville · R01 · FY2025 · AI
Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma
$2,680,780Robert S Negrin · Stanford University · P01 · FY2022 · CA
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,680,709Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2022 · AG
Chemoprophylaxis for HIV Prevention in Men
$2,680,398Robert M. Grant · J. David Gladstone Institutes · U01 · FY2007 · AI